Published online Jan 15, 2017. doi: 10.4251/wjgo.v9.i1.1
Peer-review started: August 10, 2016
First decision: September 12, 2016
Revised: September 28, 2016
Accepted: November 21, 2016
Article in press: November 22, 2016
Published online: January 15, 2017
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related mortality worldwide. HCC incidences have increased worldwide though more prevalent in Asia and Africa. Hepatitis B virus and hepatitis C virus infections are mostly responsible of increased number of HCC cases. Biomarkers can help early detection and improve treatment regimen in patients as advanced stage is chemo-refractive with limited treatment options. Potential of proteomics in finding new biomarkers for early detection has been explored more recently. Future developments in this area rely on how efficiently we manage vast amount of data generated by these techniques and speed up the clinical trials to improve patient care.
Core tip: Despite ongoing development in treatment for hepatocellular carcinoma (HCC), effective biomarkers for diagnosis and treatment for HCC are not available. Profiling of proteins puts proteomics on the forefront to understand promising new biomarkers and drug targets for HCC. HCC proteome database would be an important step towards identifying tumor associated proteins as potential therapeutic targets in the treatment of HCC.